Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 335-337

  Thodtmann R ^a,b   Theiss, F ^a   Kemmerich, M ^a   Heinrich, B ^a   Laubenbacher, C ^a   Quasthoff, S ^a   Kau, R ^a   Herzog, M ^a   Diergarten, K ^c   Hanauske, A R ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cisplatin; Head and neck cancer; Paclitaxel; Phase II trial

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 7144263711     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008298915121     Document Type: Article

References (10)

1. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
2. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 1994; 21 (Suppl 8): 49-52.
3. Hitt R, Hornedo J, Colomer R et al. A phase I-II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: Preliminary results. Semin Oncol 1995; 22 (Suppl 15): 50-4.
4. Benner SE, Lippman SM, Huber MH et al. Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. Semin Oncol 1995; 22 (Suppl 12): 22-5.
5. Schilling T, Heinrich B, Kau R et al. Paclitaxel administered over three hours followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: A clinical phase 1 study. Oncology 1997; 54: 89-95.
6. Postman TJ, Vermorken JB, Liefting AJM et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
7. Laubenbacher C, Saumweber D, Wagner-Manslau C et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36: 1747-57.
8. Investigators handbook. A manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment. NCI 1996.
9. Baker M. Bostock H. Depolarization changes the mechanisms of accommodation in rat and human motor axons. J Physiol 1989; 411: 545-61.
10. Rowinsky E, Eisenhauer EE, Chaudry Vet al. Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol 1993: 20 (Suppl 3): 1-15.